Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06745583). This is a study registration, not published results. Lead sponsor: Elixiron Immunotherapeutics Inc.. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 7 participants (ACTUAL). Conditions: Mild, Moderate, or Severe Alzheimer's Disease. Interventions: DRUG: EI-1071 tablet, oral. Primary outcome measures: To assess the change of neuroinflammation in brains of AD patients after dosing with EI-1071 by PET , Baseline, Day 28. Brief summary: An open-label, exploratory, phase II, proof-of concept, clinical study to assess the safety and tolerability of EI-1071 and the effects of EI-1071 on neuroinflammation in patients with mild, moderate, or severe Alzheimer's disease